Don’t like a court order? Sidestep it. That seems to be the idea behind U.S. Health and Human Services Secretary Robert Kennedy’s latest changes to his renewal of the charter for the CDC’s Advisory Committee on Immunization Practices (ACIP).
Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor.
German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.
Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Cocrystal, Context, Fore, Eli Lilly, Merck, Ultragenyx, Zeto.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Adagene, Axsome, Boston Scientific, BSM, Ellipsys, Gilead, Incyte, Lupin, Oncotelics, Phil, Shionogi, Takeda, Tanabe, Techforce, Tenpoint, Valencia, Visufarma.
Clinical updates for biopharma and med tech, including data readouts and publications: Adagene, Alto Neuroscience, Astrazeneca, Beam, Immunovant, Lipocine, Neutrolis, Novo Nordisk, Pangia, Puretech, Seaport, Soligenix, Vascarta.
Biopharma and med-tech companies raising money in public or private financings, including: Adagene, Arch Biopartners, Celldex, Entera, Hoth, Inovio, Stairmed.
RSS
